Invest in BioSuperior Technology, Inc.

Revolutionizing Pulmonary Care and Saving the Lives of Pre-term Infants

EARLY BIRD TERMS: $74,700 LEFT

$25,300

of a $100,000 goal
INVESTMENT TERMS
Future Equity
$10M valuation cap
Early Bird Bonus: The first $100K of investments will be in a SAFE with a $13M valuation cap and 25% discount
$250, $500, $1K, $10K
Pitch Video
Investor Panel

Highlights

1
We are developing a first-in-class therapeutic for the treatment of Bronchopulmonary Dysplasia.
2
Our drug candidate will be eligible for orphan drug designation by the FDA.
3
We have performed the first ever synthesis of lung specific proteins that make lung surfactant work.
4
We have received grants from the National Science Foundation and the March of Dimes.

Our Team

Several of us have had family members develop serious illness and pass as a result of Acute Lung Injury. We are deeply concerned with the standard of care in respiratory medicine and believe that we can substantively improve this situation.

Pitch

Downloads

Overview